Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03503474Completed

COMBACTE-CDI Understanding the Burden of C. Difficile Infection

Role: collaborator

NCT02896244Completed

AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment

Role: collaborator

NCT02176005Phase 1Completed

Safety and Efficacy Study of DAV132 in Healthy Volunteers

Role: lead

NCT03710694Not ApplicableCompleted

Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)

Role: lead

NCT02917200Phase 1Completed

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

Role: lead

NCT01591538Completed

Multi-Antibiotic Resistance Carriage in Gut Flora

Role: lead

All 6 trials loaded